Androgens in premenopausal women and women with premature ovarian insufficiency. (3rd September 2021)

• Record Type: Journal Article
• Authors: Davis, S. R.
• Is Part Of: Climacteric. Volume 24:Number 5(2021)
• Page Start: 459
• Page End: 465
• Publication Date: 2021-09-03
• Subjects: Testosterone -- androgens -- premature ovarian insufficiency -- menopause; Menopause -- Periodicals; Menopause -- Hormone therapy -- Periodicals; Menopause -- Periodicals; Estrogen Replacement Therapy -- Periodicals; Gynecology -- Periodicals; Societies, Medical -- Periodicals; 612.665
• DOI: 10.1080/13697137.2020.1866530
• Languages: English
• ISSNs: 1369-7137

Abstract

Abstract: Premature ovarian insufficiency (POI) results in both estrogen and testosterone insufficiency. Whether testosterone therapy may be of benefit for women with POI is uncertain. Presently, the only evidence-based indication for testosterone therapy for women is for the treatment of postmenopausal women with low sexual desire with associated personal distress. Consistent with this, available evidence does not support the prescription of testosterone to prevent cardiometabolic disease, bone loss, sarcopenia, or cognitive decline or to improve well-being and low mood in postmenopausal women. Data pertaining to the treatment of women with POI with testosterone are limited. This article reviews androgen physiology in premenopausal women and the impact of POI on circulating androgen concentrations, summarizes findings from observational studies and clinical trials of testosterone therapy in premenopausal women and women with POI, and concludes with recommendations regarding testosterone use in women with POI.